This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Metformin for Treatment of Antipsychotic-induced Dyslipidemia

This study has been completed.
Information provided by (Responsible Party):
Jingping Zhao, Central South University Identifier:
First received: January 19, 2013
Last updated: January 25, 2013
Last verified: January 2013
Almost all antipsychotics can induce dyslipidemia, but no treatment has been established. Metformin can improve lipid levels in obese patients. The investigators conducted a randomized, placebo-controlled study to test the efficacy of metformin for antipsychotic-induced dyslipidemia.

Condition Intervention Phase
Dyslipidemia Drug: metformin Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Metformin for Treatment of Antipsychotic-induced Dyslipidemia: a Randomized, Double-blind Study

Resource links provided by NLM:

Further study details as provided by Jingping Zhao, Central South University:

Primary Outcome Measures:
  • low-density lipoprotein cholesterol [ Time Frame: 8 weeks ]

Secondary Outcome Measures:
  • high-density lipoprotein cholesterol [ Time Frame: 8 weeks ]
  • adverse effects [ Time Frame: 8 weeks ]

Other Outcome Measures:
  • body mass index [ Time Frame: 8 weeks ]

Enrollment: 162
Study Start Date: November 2008
Study Completion Date: June 2012
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: metformin
Drug: metformin
1000mg/day for 24 weeks
Placebo Comparator: placebo

Detailed Description:
The study was designed as a double-blind randomized controlled trial, with research assessors and patients intended to be blind to the intervention status. The staff members performing the assessment were not involved in implementing any aspect of the intervention.162 patients were randomized to one of two 24-week individual treatments: metformin (1000mg/day)or placebo. Medications were provided in double-blind fashion.The assessments include lipid levels, body weight, body mass index, fasting glucose, fasting insulin and insulin resistance index.

Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Diagnostic and Statistical Manual of Mental Disorder-Fourth Edition (DSM-Ⅳ) criteria for schizophrenia dyslipidemia after antipsycotic treatment the duration of illness was less than 12 months taking only one antipsychotic stable outpatient the total score of Positive and Negative Syndrome Scale (PANSS)≤60.

Exclusion Criteria:

liver or renal diseases pregnant or lactating women cardiovascular diseases hypertension or diabetes mellitus

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01778244

China, Hunan
Institute of Mental Health of The Second Xiangya Hospital, Central South University
Changsha, Hunan, China, 410011
Sponsors and Collaborators
Central South University
Principal Investigator: Renrong Wu, MD Central South University
  More Information

Responsible Party: Jingping Zhao, professor, Central South University Identifier: NCT01778244     History of Changes
Other Study ID Numbers: RRWu
Study First Received: January 19, 2013
Last Updated: January 25, 2013

Keywords provided by Jingping Zhao, Central South University:
schizophrenia; dyslipidemia

Additional relevant MeSH terms:
Lipid Metabolism Disorders
Metabolic Diseases
Antipsychotic Agents
Hypoglycemic Agents
Physiological Effects of Drugs
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs processed this record on September 21, 2017